Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.20529/IJME.2021.025 http://scihub22266oqcxt.onion/10.20529/IJME.2021.025 33908351!?!33908351 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33908351&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Indian+J+Med+Ethics 2021 ; VI (2): 1-6 Nephropedia Template TP {{tp|p=33908351|t=2021. Placebo in new Covid-19 vaccine trials: data quality prioritised over participants rights |pdf=|usr=}}{{33908351}} gab.com Text Placebo in new Covid-19 vaccine trials: data quality prioritised over participants rights JO: Indian J Med Ethics http://www.kidney.de/pget.php?&tw=1&pmid=33908351 #FOAvip The WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation makes recommendations on the use of placebo controlled trials in ongoing and future Covid-19 vaccine research. These recommendations unequivocally prioritise data quality over participants' rights and safety. Participants in trials of vaccines which have received emergency use listing or authorisation would be refused available vaccines. Placebo-controlled trials that would be impossible to conduct in rich countries would be permitted in poor countries. If these suggestions are implemented, the major beneficiary will be the vaccine industry. Twit Text FOAVip Placebo in new Covid-19 vaccine trials: data quality prioritised over participants rights ????Indian J Med Ethics http://www.kidney.de/pget.php?&tw=1&pmid=33908351 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33908351 #FOAvip English Wikipedia <ref>{{Cite pmid|33908351}}</ref> Placebo in new Covid-19 vaccine trials: data quality prioritised over participants rights #MMPMID33908351 Srinivasan S Indian J Med Ethics 2021[Apr]; VI (2): 1-6 PMID33908351show ga The WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation makes recommendations on the use of placebo controlled trials in ongoing and future Covid-19 vaccine research. These recommendations unequivocally prioritise data quality over participants' rights and safety. Participants in trials of vaccines which have received emergency use listing or authorisation would be refused available vaccines. Placebo-controlled trials that would be impossible to conduct in rich countries would be permitted in poor countries. If these suggestions are implemented, the major beneficiary will be the vaccine industry. |*Ethics, Medical[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Biomedical Research[MESH] |COVID-19 Vaccines/*standards[MESH] |COVID-19/*prevention & control[MESH] |Data Accuracy[MESH] |Female[MESH] |Guidelines as Topic[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Patient Rights/*ethics/*standards[MESH] |Placebos/*standards[MESH]Placebo in new Covid-19 vaccine trials: data quality prioritised over (epmc).pdf DeepDyve Pubget Overpricing